Deuremidevir hydrobromide

氢溴酸氘瑞米德韦

Report date: 2026/05/26 15:57:06
NME

Base Information

Drug NameDeuremidevir hydrobromide
Drug Alias NameMindeudesivir hydrobromide仁明德韦Deuterium Hydrobromide RamidvirDeuterium remidevirDeuremidevir hydrobromide +[16] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analoguesSmall molecules > Deuterated drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitorsViral proteins inhibitors
TargetsRNA-directed RNA polymeraseViral proteins
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Syncytial Virus InfectionsHenipavirus Infections
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryUzbekistan
Original Approved Date2021/12/31
Country/TerritoryUzbekistanHong KongMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesWuhan Institute Of Virology, Chinese Academy Of SciencesThe Xinjing Technical Institute Of Physics & Chemistry.Cas +[4] 
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuhan Institute Of Virology, Chinese Academy Of SciencesShanghai Wangshi Biomedicine Technology Co LtdSimcere Pharmaceutical Co Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Syncytial Virus InfectionsHenipavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A